Logo image of METEX.PA

Metabolic Explorer (METEX.PA) Stock Fundamental Analysis

EPA:METEX - Euronext Paris - Matif - FR0004177046 - Common Stock - Currency: EUR

0.1214  +0 (+1.17%)

Fundamental Rating

2

Overall METEX gets a fundamental rating of 2 out of 10. We evaluated METEX against 62 industry peers in the Chemicals industry. METEX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, METEX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year METEX has reported negative net income.
In the past year METEX has reported a negative cash flow from operations.
METEX had negative earnings in 4 of the past 5 years.
In the past 5 years METEX reported 4 times negative operating cash flow.
METEX.PA Yearly Net Income VS EBIT VS OCF VS FCFMETEX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M 80M

1.2 Ratios

METEX has a worse Return On Assets (-19.08%) than 89.06% of its industry peers.
METEX has a worse Return On Equity (-51.84%) than 89.06% of its industry peers.
Industry RankSector Rank
ROA -19.08%
ROE -51.84%
ROIC N/A
ROA(3y)-0.39%
ROA(5y)-4.87%
ROE(3y)-8.69%
ROE(5y)-13.58%
ROIC(3y)N/A
ROIC(5y)N/A
METEX.PA Yearly ROA, ROE, ROICMETEX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20 40 -40

1.3 Margins

METEX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
METEX.PA Yearly Profit, Operating, Gross MarginsMETEX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

METEX does not have a ROIC to compare to the WACC, probably because it is not profitable.
METEX has about the same amout of shares outstanding than it did 1 year ago.
METEX has a worse debt/assets ratio than last year.
METEX.PA Yearly Shares OutstandingMETEX.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
METEX.PA Yearly Total Debt VS Total AssetsMETEX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

METEX has an Altman-Z score of 0.19. This is a bad value and indicates that METEX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of METEX (0.19) is worse than 90.63% of its industry peers.
A Debt/Equity ratio of 0.92 indicates that METEX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.92, METEX is doing worse than 79.69% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF N/A
Altman-Z 0.19
ROIC/WACCN/A
WACC5.97%
METEX.PA Yearly LT Debt VS Equity VS FCFMETEX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 2.19 indicates that METEX has no problem at all paying its short term obligations.
METEX has a better Current ratio (2.19) than 64.06% of its industry peers.
A Quick Ratio of 1.31 indicates that METEX should not have too much problems paying its short term obligations.
METEX has a Quick ratio (1.31) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.31
METEX.PA Yearly Current Assets VS Current LiabilitesMETEX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M

More info and screens

4

3. Growth

3.1 Past

METEX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -137.50%.
METEX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -36.59%.
METEX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 123.77% yearly.
EPS 1Y (TTM)-137.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
Revenue 1Y (TTM)-36.59%
Revenue growth 3Y765.1%
Revenue growth 5Y123.77%
Sales Q2Q%-46.56%

3.2 Future

METEX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.69% yearly.
METEX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.34% yearly.
EPS Next Y1.9%
EPS Next 2Y23.83%
EPS Next 3Y23.69%
EPS Next 5YN/A
Revenue Next Year-44.08%
Revenue Next 2Y-9.58%
Revenue Next 3Y2.34%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
METEX.PA Yearly Revenue VS EstimatesMETEX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
METEX.PA Yearly EPS VS EstimatesMETEX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2018 2019 2020 2021 2022 2023 2024 2025 0 0.2 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for METEX. In the last year negative earnings were reported.
Also next year METEX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
METEX.PA Price Earnings VS Forward Price EarningsMETEX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
METEX.PA Per share dataMETEX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as METEX's earnings are expected to grow with 23.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.83%
EPS Next 3Y23.69%

More info and screens

0

5. Dividend

5.1 Amount

METEX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Metabolic Explorer

EPA:METEX (5/6/2024, 7:00:00 PM)

0.1214

+0 (+1.17%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)05-14 2024-05-14
Earnings (Next)07-25 2024-07-25
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap6.16M
Analysts34.29
Price Target0.2 (64.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-55.56%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)12.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.08
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS3.28
BVpS1.88
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.08%
ROE -51.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-0.39%
ROA(5y)-4.87%
ROE(3y)-8.69%
ROE(5y)-13.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 254.32%
Cap/Sales 9.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 1.31
Altman-Z 0.19
F-Score2
WACC5.97%
ROIC/WACCN/A
Cap/Depr(3y)1451.31%
Cap/Depr(5y)1065.24%
Cap/Sales(3y)15548.8%
Cap/Sales(5y)10277%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-137.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
EPS Next Y1.9%
EPS Next 2Y23.83%
EPS Next 3Y23.69%
EPS Next 5YN/A
Revenue 1Y (TTM)-36.59%
Revenue growth 3Y765.1%
Revenue growth 5Y123.77%
Sales Q2Q%-46.56%
Revenue Next Year-44.08%
Revenue Next 2Y-9.58%
Revenue Next 3Y2.34%
Revenue Next 5YN/A
EBIT growth 1Y-165.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.98%
EBIT Next 3Y37.59%
EBIT Next 5YN/A
FCF growth 1Y-192.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3320.34%
OCF growth 3YN/A
OCF growth 5YN/A